CN113383074A - Caix特异性的双环肽配体 - Google Patents
Caix特异性的双环肽配体 Download PDFInfo
- Publication number
- CN113383074A CN113383074A CN202080009486.9A CN202080009486A CN113383074A CN 113383074 A CN113383074 A CN 113383074A CN 202080009486 A CN202080009486 A CN 202080009486A CN 113383074 A CN113383074 A CN 113383074A
- Authority
- CN
- China
- Prior art keywords
- seq
- referred
- iii
- sar
- peptide ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900526.3 | 2019-01-15 | ||
| GBGB1900526.3A GB201900526D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for caix |
| PCT/GB2020/050070 WO2020148526A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for caix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113383074A true CN113383074A (zh) | 2021-09-10 |
Family
ID=65528170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080009486.9A Pending CN113383074A (zh) | 2019-01-15 | 2020-01-15 | Caix特异性的双环肽配体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220133732A1 (enExample) |
| EP (1) | EP3911743A1 (enExample) |
| JP (1) | JP2022517442A (enExample) |
| CN (1) | CN113383074A (enExample) |
| GB (1) | GB201900526D0 (enExample) |
| WO (1) | WO2020148526A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117120458A (zh) * | 2022-02-11 | 2023-11-24 | C-比奥麦克斯有限公司 | 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途 |
| WO2024041535A1 (zh) * | 2022-08-22 | 2024-02-29 | 赣州和美药业股份有限公司 | 纳米组合物及其制备方法和用途 |
| CN120230182A (zh) * | 2025-05-29 | 2025-07-01 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽及其核素标记物与应用 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3215518T1 (sl) | 2014-10-29 | 2021-08-31 | Bicyclerd Limited | Biciklični peptidni ligandi, značilni za MT1-MMP |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| WO2019162682A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128526A1 (en) | 2018-12-21 | 2020-06-25 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AR128023A1 (es) | 2021-12-17 | 2024-03-20 | 3B Pharmaceuticals Gmbh | Ligandos de anhidrasa carbónica ix |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017191460A1 (en) * | 2016-05-04 | 2017-11-09 | Bicycle Therapeutics Limited | Bicyclic peptide-toxin conjugates specific for mt1-mmp |
| WO2019002842A1 (en) * | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| PL1844337T3 (pl) | 2005-01-24 | 2013-12-31 | Pepscan Systems Bv | Związki wiążące, związki immunogenne i peptydomimetyki |
| ES2509959T5 (en) | 2008-02-05 | 2024-12-19 | Bicyclerd Ltd | Methods and compositions |
| SI3215518T1 (sl) | 2014-10-29 | 2021-08-31 | Bicyclerd Limited | Biciklični peptidni ligandi, značilni za MT1-MMP |
| EP3615550A1 (en) * | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
-
2019
- 2019-01-15 GB GBGB1900526.3A patent/GB201900526D0/en not_active Ceased
-
2020
- 2020-01-15 EP EP20701119.8A patent/EP3911743A1/en not_active Withdrawn
- 2020-01-15 JP JP2021563433A patent/JP2022517442A/ja active Pending
- 2020-01-15 US US17/422,933 patent/US20220133732A1/en not_active Abandoned
- 2020-01-15 CN CN202080009486.9A patent/CN113383074A/zh active Pending
- 2020-01-15 WO PCT/GB2020/050070 patent/WO2020148526A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017191460A1 (en) * | 2016-05-04 | 2017-11-09 | Bicycle Therapeutics Limited | Bicyclic peptide-toxin conjugates specific for mt1-mmp |
| WO2019002842A1 (en) * | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117120458A (zh) * | 2022-02-11 | 2023-11-24 | C-比奥麦克斯有限公司 | 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途 |
| WO2024041535A1 (zh) * | 2022-08-22 | 2024-02-29 | 赣州和美药业股份有限公司 | 纳米组合物及其制备方法和用途 |
| CN120230182A (zh) * | 2025-05-29 | 2025-07-01 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽及其核素标记物与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3911743A1 (en) | 2021-11-24 |
| US20220133732A1 (en) | 2022-05-05 |
| WO2020148526A1 (en) | 2020-07-23 |
| GB201900526D0 (en) | 2019-03-06 |
| JP2022517442A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113383074A (zh) | Caix特异性的双环肽配体 | |
| JP7460523B2 (ja) | EphA2に特異的な二環ペプチドリガンド | |
| US10994019B2 (en) | Bicyclic peptide-toxin conjugates specific for MT1-MMP | |
| CN113383007A (zh) | Caix特异性的双环肽配体 | |
| JP7658902B2 (ja) | Pd-l1に特異的な二環式ペプチドリガンド | |
| CN113507960A (zh) | Psma特异性的双环肽配体 | |
| CN114521197A (zh) | 异串联双环肽复合物 | |
| CN113613728A (zh) | 整联蛋白αvβ3特异性的双环肽配体 | |
| CN113474045A (zh) | Pd-l1特异性的双环肽配体 | |
| CN113543813B (zh) | Cd38特异性的双环肽配体 | |
| CN113439088A (zh) | 整联蛋白αvβ3特异性的双环肽配体 | |
| CN114787197A (zh) | 修饰的多聚双环肽配体 | |
| CN113811541A (zh) | Ox40特异性的双环肽配体 | |
| CN112585157A (zh) | 用于结合整联蛋白αvβ3的肽配体 | |
| CN113518648A (zh) | Mt1-mmp特异性的双环肽配体 | |
| CN113474046A (zh) | Il-17特异性的双环肽配体 | |
| CN113507961A (zh) | FAPα特异性的双环肽配体 | |
| CN114829376A (zh) | Il-17特异性的双环肽配体 | |
| CN114867736A (zh) | Il-17特异性的双环肽配体 | |
| CN114787176A (zh) | Il-17特异性的双环肽配体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210910 |
|
| WD01 | Invention patent application deemed withdrawn after publication |